These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
681 related articles for article (PubMed ID: 31784805)
21. The Past and Future of Psychedelic Science: An Introduction to This Issue. Doblin RE; Christiansen M; Jerome L; Burge B J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970 [TBL] [Abstract][Full Text] [Related]
22. The renaissance in psychedelic research: What do preclinical models have to offer. Murnane KS Prog Brain Res; 2018; 242():25-67. PubMed ID: 30471682 [TBL] [Abstract][Full Text] [Related]
23. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Carhart-Harris RL; Goodwin GM Neuropsychopharmacology; 2017 Oct; 42(11):2105-2113. PubMed ID: 28443617 [TBL] [Abstract][Full Text] [Related]
24. Classical psychedelics for the treatment of depression and anxiety: A systematic review. Muttoni S; Ardissino M; John C J Affect Disord; 2019 Nov; 258():11-24. PubMed ID: 31382100 [TBL] [Abstract][Full Text] [Related]
26. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Johnson MW; Hendricks PS; Barrett FS; Griffiths RR Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880 [TBL] [Abstract][Full Text] [Related]
27. Psychedelics: Where we are now, why we got here, what we must do. Belouin SJ; Henningfield JE Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779 [TBL] [Abstract][Full Text] [Related]
28. Psychedelic-assisted therapies: The past, and the need to move forward responsibly. Gardner J; Carter A; O'Brien K; Seear K Int J Drug Policy; 2019 Aug; 70():94-98. PubMed ID: 31136924 [TBL] [Abstract][Full Text] [Related]
29. Sustained effects of single doses of classical psychedelics in humans. Knudsen GM Neuropsychopharmacology; 2023 Jan; 48(1):145-150. PubMed ID: 35729252 [TBL] [Abstract][Full Text] [Related]
30. Microdosing psychedelics: Motivations, subjective effects and harm reduction. Lea T; Amada N; Jungaberle H; Schecke H; Klein M Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967 [TBL] [Abstract][Full Text] [Related]
31. Therapeutic Applications of Classic Hallucinogens. Bogenschutz MP; Ross S Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684 [TBL] [Abstract][Full Text] [Related]
32. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. Reiche S; Hermle L; Gutwinski S; Jungaberle H; Gasser P; Majić T Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():1-10. PubMed ID: 28947181 [TBL] [Abstract][Full Text] [Related]
33. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. Lyvers M; Meester M J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892 [TBL] [Abstract][Full Text] [Related]
34. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation. Johnson MW Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271 [TBL] [Abstract][Full Text] [Related]
35. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. Corrigan K; Haran M; McCandliss C; McManus R; Cleary S; Trant R; Kelly Y; Ledden K; Rush G; O'Keane V; Kelly JR Ir J Med Sci; 2022 Jun; 191(3):1385-1397. PubMed ID: 34131812 [TBL] [Abstract][Full Text] [Related]
36. Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology. Kelly DF; Heinzerling K; Sharma A; Gowrinathan S; Sergi K; Mallari RJ Neurosurgery; 2023 Apr; 92(4):680-694. PubMed ID: 36512813 [TBL] [Abstract][Full Text] [Related]
37. [Psychedelics for existential distress in terminally ill patients]. Schimmel N; Breeksema JJ; Veraart JKE; van den Brink W; Schoevers RA Tijdschr Psychiatr; 2020; 62(8):659-668. PubMed ID: 32816294 [TBL] [Abstract][Full Text] [Related]
39. Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities. Yaden DB; Johnson MW; Griffiths RR; Doss MK; Garcia-Romeu A; Nayak S; Gukasyan N; Mathur BN; Barrett FS Int J Neuropsychopharmacol; 2021 Aug; 24(8):615-623. PubMed ID: 33987652 [TBL] [Abstract][Full Text] [Related]
40. Psychedelics and Dying Care: A Historical Look at the Relationship between Psychedelics and Palliative Care. Dyck E J Psychoactive Drugs; 2019; 51(2):102-107. PubMed ID: 30821651 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]